User:Haroldok/sandbox

Frederick Dominick Sancilio (March 15, 1950) is an American pharmaceutical scientist, author, research professor, and serial entrepreneur. He founded several biotechnology and contract research organizations from 1979 to 2023. His first notable entrepreneurial venture was Applied Analytical Industries, Inc. (AAI), now Alcami, an American non-clinical pharmaceutical contract research organization focused on drug product development activities; he founded the company and served as the director, chairman, and chief executive officer. He is currently an adjunct biotechnology research professor at Florida Atlantic University and president of Clearway Global, LLC.

Early life and education
Sancilio was born on March 15, 1950, in New Jersey. His parents were Joseph and Lina Sancilio; both were from Italy. He has two brothers, namely Cresent and Mario. He went to Hoboken High School for his secondary education. He subsequently attended Rutgers University and earned his bachelor's, master's, and doctorate degrees in chemistry.

Career
Sancilio's introduction to his pharmaceutical research career began in 1969 during his undergraduate studies at Rutgers University where he worked with Dr. Al Steyermark— a once renowned innovator, editor of The Microchemical Journal, a visiting professor, and former assistant to the president of Hoffman-LaRoche, Inc.— in his micro-analytical laboratory. In 1972, their odyssey working together led to Sancilio's new job at Hoffman-LaRoche where he contributed to several research programs as a physical chemist and x-ray crystallographer. In 1975, Sancilio was recruited as a research manager at Schering-Plough Corporation where he contributed to various product development programs. A year later, he became the head of quality control laboratory operations at Burroughs-Welcome company where he helped resolve a severe regulatory conflict with the US FDA.

He is a biotechnology research professor at Florida Atlantic University and the current prexy of Clearway Global, LLC., since 2019. He is also the principal owner, operating partner, and consulting arm of one of his founded companies, Sancilio & Company, Inc.

Applied Analytical Industries (AAI)
In 1979, Sancilio established his first company, Applied Analytical Industries (AAI), in Greenville, North Carolina. AAI was an American non-clinical contract research organization to offer laboratory services to pharmaceutical companies. A year later, laboratory operations were moved to Wilmington, North Carolina. The company grew to over 1,000 employees before Sancilio's retirement as chief executive officer in 2002. Circa 2013, the Cambridge Major Laboratories, Inc. (CML) and AAI joined together as Alcami. It continues to provide global pharmaceutical research services.

Endeavor Pharmaceuticals
In 1994, Sancilio founded Endeavor Pharmaceuticals and became its first chief executive officer. The company was funded by venture capital provided by Goldman Sachs, Schering Corporation AG, and others. It was later acquired by Barr Laboratories, now Teva.

Aesgen Pharmaceuticals
In 1995, Sancilio founded Aesgen Pharmaceuticals and became its chief executive officer. Aesgen was a joint enterprise between AAI and Mayo Clinic's Mayo Medical Ventures. It was funded by Goldman Sachs and others. It was later acquired by a public drug company and merged into Pfizer.

Sancilio & Company, Inc. (SCI)
In 2005, Sancilio established Sancilio & Company, Inc. (SCI) in Jupiter, Florida. It was a pharmaceutical company that markedly specialized in developing and manufacturing medical dietary supplements and medicines for women and children. He grew the firm until it was acquired by investors in 2017. SCI was reorganized and renamed Micelle Biopharma.

Clearway Global, LLC.
In 2019, Sancilio established a virtual contract research organization called Clearway Global, LLC. with the vision of leveraging his global network of research services into a cost-effective offering to entrepreneurial biotechnology companies to enable research to be done at a fraction of the cost of brick-and-mortar contractors. He is currently the prexy of the company.

Awards and Honours
In 1995 and 1996, Ernst & Young, a global professional services partnership, held its annual Entrepreneur of the Year award which Sancilio clinched 2nd and 1st places, respectively.

Publications
Sancilio published a book entitled "Prevention is the Cure! A Scientist's Guide to Extending Your Life" in 2011. It discusses the nature of health and sickness; understanding how people become ill and what we can do to avoid it from a scientist's point of view. Sancilio's other publications are listed below.


 * A Quantitative-EEG Assessment of Alpha-1062, a Novel Pro-Drug of Galantamine for the Treatment of Mild to Moderate Dementia Associated with Alzheimer’s Disease. (2023, November 28). Alzheimher’s Association. Retrieved January 13, 2024, from https://alz-journals.onlinelibrary.wiley.com/doi/abs/10.1002/alz.068223
 * Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro. (2021, September 10). Nature. Retrieved January 13, 2024, from https://www.nature.com/articles/s41598-021-97658-w
 * SC411 treatment can enhance survival in a mouse model of sickle cell disease. (2020, April 14). Science Direct. Retrieved January 13, 2024, from https://www.sciencedirect.com/science/article/pii/S0952327820300685
 * Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance. (2017, February 8). Science Direct. Retrieved January 13, 2024, from https://www.sciencedirect.com/science/article/abs/pii/S0149291817300577
 * Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3–acid ethyl esters with an Advanced Lipid TechnologiesTM (ALT®)–based formulation. (2017, February 9). Science Direct. Retrieved January 13, 2024, from https://www.sciencedirect.com/science/article/abs/pii/S1933287417300223
 * "Development and Validation of a Single HPLC Method for Analysis of Purines in Fish Oil Supplements ". (2013, December). Scientific Research. Retrieved January 13, 2024, from https://pdfs.semanticscholar.org/1e71/4592731b1d076368d5dd2d9029b9cf8ce77f.pdf
 * A Dietary Supplement with a High Eicosapentaenoic Acid to Docosahexaenoic Acid Ratio Reduces Triglyceride Levels in Mildly Hypertriglyceridemic Subjects. (2012, December 2). Scientific Research. Retrieved January 13, 2024, from https://www.scirp.org/html/2-2700586_26454.htm
 * Gentamicin C-component ratio determination by high-pressure liquid chromatography. (2002, January 4). Science Direct. Retrieved January 13, 2024, from https://www.sciencedirect.com/science/article/abs/pii/S0021967300955092
 * Thermally-Prepared Polymorphic Forms of Cilostazol. (2002, July 5). Science Direct. Retrieved January 13, 2024, from https://www.sciencedirect.com/science/article/abs/pii/S002235491631125X
 * High-performance liquid chromatographic analysis of trimethoprim and sulfamethoxazole in dosage forms. (1980, February). Wiley Online Library. Retrieved January 13, 2024, from https://onlinelibrary.wiley.com/doi/abs/10.1002/jps.2600690206
 * The Synthesis, Structure and Properties of some Triazido Triammine Complexes of Cobalt(Iii). (1979). E Library. Retrieved January 13, 2024, from https://elibrary.ru/item.asp?id=7237936
 * The megalomicins. Part 7. A structural revision by carbon-13 nuclear magnetic resonance and X-ray crystallography. Synthesis and conformational analysis of 3-dimethylamino- and 3-azido-D- and -L-hexopyranosides, and the crystal structure of 4″-O-(4-lodobenzoyl)megalomicin A. (1979). Publishing. Retrieved January 13, 2024, from https://pubs.rsc.org/en/content/articlelanding/1979/p1/p19790001600/unauth
 * Analysis of steroid phosphates by high-pressure liquid chromatography: Betamethasone sodium phosphate. (1978, July). Wiley Online Library. Retrieved January 13, 2024, from https://onlinelibrary.wiley.com/doi/abs/10.1002/jps.2600670710
 * A short synthesis of aromatic analogs of the aranotins. (1977, March 1). ACS Publications. Retrieved January 13, 2024, from https://pubs.acs.org/doi/pdf/10.1021/jo00426a004
 * Triamines of cobalt(III). 5. Nuclear magnetic resonance characterization of diethylenetriaminecobalt(III) complexes and the structure of meridional bis(diethylenetriamine)cobalt(III) nitrate monohydrate. (1976, July 1). ACS Publications. Retrieved January 13, 2024, from https://pubs.acs.org/doi/pdf/10.1021/ic50161a031
 * Quantitative polarographic determination of azides in cobalt(III) coordination complexes. (1975, January 1). https://pubs.acs.org/doi/pdf/10.1021/ac60351a023 . Retrieved January 13, 2024, from https://pubs.acs.org/doi/pdf/10.1021/ac60351a023
 * Triamines of cobalt(III). III. The crystal structure of Co(dien)(N3)3. (1974, May 29). Structural Science, Crystal Engineering and Materials. Retrieved January 13, 2024, from https://scripts.iucr.org/cgi-bin/paper?a11286
 * Quinazolines and 1,4-benzodiazepines. 64. Comparison of the stereochemistry of diazepam with that of close analogs with marginal biological activity. (1974, March 1). ACS Publications. Retrieved January 13, 2024, from https://pubs.acs.org/doi/pdf/10.1021/jm00249a032
 * The Triamines of Cobalt[Iii]. Ii. Infrared and Nuclear Magnetic Resonance Spectra of some Azido Complexes. (1973, January 29). Taylor and Francis Online. Retrieved January 13, 2024, from https://www.tandfonline.com/doi/abs/10.1080/00958977308073794
 * Triamines of Cabalt (Iii). Iii. The Crystal Structures of Mer-Triazidodiethylenetriaminecobalt (Iii), Co(Dien) (N3)3.(n.d.). Pascal and Francis. Retrieved January 13, 2024, from https://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=PASCAL7540075158